Longford-Westmeath TD Calls For Skyclarys Compassionate Access Scheme

Micheál Carrigy has met with Biogen which manufactures the drug for Friedreich's Ataxia.

There's a call on the provider of a drug for Friedreich's ataxia to consider a compassionate access scheme. 

Negotiations are currently underway between the HSE and Biogen regarding the cost of supplying Skyclarys. 

However, the HSE has upheld a recommendation not to reimburse the drug, as it would cost around 280 thousand euro per patient per year. 

Fine Gael's Micheál Carrigy met with Biogen, and is recommending an alternative step: 

More from Midlands News

Download Our App